Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Receives Consensus Rating of "Moderate Buy" from Analysts

Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Get Free Report) have been given an average rating of "Moderate Buy" by the five brokerages that are presently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 1-year price objective among analysts that have covered the stock in the last year is $43.80.

Several analysts recently issued reports on COLL shares. StockNews.com downgraded Collegium Pharmaceutical from a "strong-buy" rating to a "buy" rating in a research note on Saturday, April 19th. Needham & Company LLC reissued a "buy" rating and issued a $46.00 target price on shares of Collegium Pharmaceutical in a research report on Wednesday, April 9th. Piper Sandler restated a "neutral" rating and issued a $37.00 price target (up from $36.00) on shares of Collegium Pharmaceutical in a research note on Friday, May 9th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $50.00 price target on shares of Collegium Pharmaceutical in a research report on Monday, March 24th.

Insider Activity

In other Collegium Pharmaceutical news, EVP Shirley R. Kuhlmann sold 40,000 shares of the stock in a transaction dated Tuesday, March 4th. The shares were sold at an average price of $28.08, for a total transaction of $1,123,200.00. Following the sale, the executive vice president now directly owns 154,204 shares in the company, valued at $4,330,048.32. This represents a 20.60% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Scott Dreyer sold 2,255 shares of the firm's stock in a transaction dated Friday, March 14th. The shares were sold at an average price of $30.00, for a total transaction of $67,650.00. Following the completion of the transaction, the executive vice president now directly owns 124,421 shares in the company, valued at approximately $3,732,630. This represents a 1.78% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 81,693 shares of company stock worth $2,334,994. 2.51% of the stock is currently owned by company insiders.

Institutional Trading of Collegium Pharmaceutical

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Uniplan Investment Counsel Inc. raised its position in Collegium Pharmaceutical by 0.6% during the first quarter. Uniplan Investment Counsel Inc. now owns 142,801 shares of the specialty pharmaceutical company's stock valued at $4,263,000 after purchasing an additional 797 shares in the last quarter. Millennium Management LLC raised its holdings in shares of Collegium Pharmaceutical by 248.5% during the 1st quarter. Millennium Management LLC now owns 647,832 shares of the specialty pharmaceutical company's stock worth $19,338,000 after buying an additional 461,914 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Collegium Pharmaceutical by 4.5% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 19,046 shares of the specialty pharmaceutical company's stock worth $569,000 after buying an additional 825 shares during the last quarter. Amundi boosted its stake in Collegium Pharmaceutical by 302.1% in the first quarter. Amundi now owns 62,592 shares of the specialty pharmaceutical company's stock valued at $1,816,000 after buying an additional 47,024 shares in the last quarter. Finally, Stonepine Capital Management LLC bought a new position in Collegium Pharmaceutical in the first quarter valued at about $615,000.

Collegium Pharmaceutical Price Performance

Shares of COLL opened at $30.23 on Friday. The company's 50-day moving average is $28.12 and its 200-day moving average is $29.85. The company has a debt-to-equity ratio of 3.43, a current ratio of 0.97 and a quick ratio of 0.88. The firm has a market capitalization of $971.35 million, a PE ratio of 13.03 and a beta of 0.63. Collegium Pharmaceutical has a fifty-two week low of $23.23 and a fifty-two week high of $42.29.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The specialty pharmaceutical company reported $1.49 earnings per share for the quarter, missing the consensus estimate of $1.50 by ($0.01). Collegium Pharmaceutical had a net margin of 14.78% and a return on equity of 104.67%. The company had revenue of $177.76 million during the quarter, compared to the consensus estimate of $174.96 million. During the same period in the prior year, the company earned $1.45 earnings per share. The firm's revenue was up 22.7% compared to the same quarter last year. Equities analysts forecast that Collegium Pharmaceutical will post 5.62 EPS for the current year.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.